old salt wrote: ↑Fri Jul 05, 2024 11:08 am
a fan wrote: ↑Fri Jul 05, 2024 10:42 am
old salt wrote: ↑Fri Jul 05, 2024 6:42 am
I did not complain about grocery monolipies. You did on my behalf. I told you how my family copes with it. I didn't complain about it - you did.
The FTC did not protect us & we don't need them to. They'd force us to go union, against the wishes of our employees.
More gaslighting.....you recognize how much harder things were made by the monopolies, and pointed it out, and told me the FTC did nothing.
You understand just fine. "Force us to go union".
Nothing like just making stuff up to try and virtue signal.
old salt wrote: ↑Thu Jul 04, 2024 4:31 pm
I also pointed out how ridiculous it is to compare an industry leading Genomics company with an independent family grocery store.
Don't care. That's your OPINION, masquerading as fact. You're convinced that because you say something, it's a fact...which is why you ignore anything anyone here posts, and trundle ahead. No thought. No pause. Not an ounce of hubris.
old salt wrote: ↑Thu Jul 04, 2024 4:31 pm
My Motivations ? Selfish-Ocracy ?
I don't seek or need more money.
Right. Yet you've now posted dozens of times showing you're clearly outraged to the point where you called the clearly qualified FTC Chair a "DEI hire". Either you are REALLY mad, or you're a racist. Pick one.
And we both know you're not a racist. This is transparently about money. If the value of the stock had remained unchanged? You wouldn't have so much as noticed what the FTC did. Trying to sell the forum on any other motivation is a waste of time. You want more money. Period.
And again.....that's fine. This is America. I wish you and your family all the success in the world.
You're right -- I'm REALLY mad. ...not at the lost money but losing the amount of good things we could have done with it.
I'm aware that you should never invest money in stocks that you can't afford to lose. We factored that in when we bought & retained ILMN.
By all metrics, it was a rock solid long term play.
No risk factors. No way to anticipate Khan's overreach. It was unprecedented in many ways.
Her hiring & trustbusting is part of a DEI agenda.
RISK FACTORS
1) Our continued growth is dependent on continuously developing and commercializing new products.
2) Our success depends upon the continued emergence and growth of markets for analysis of genetic variation, and continued substantial increases in the use of sequencing as the cost of sequencing declines.
3) If we do not successfully manage the development, manufacturing, and launch of new products or services, including product
transitions, our financial results could be adversely affected.
4) We face intense competition, which could render our products obsolete, result in significant price reductions, or substantially limit the
volume of products that we sell.
5) As we develop, market, or sell diagnostic tests, we may encounter delays in receipt, or limits in the amount, of reimbursement
approvals and public health funding, which will impact our ability to grow revenues in the healthcare market.
6) We depend on third-party manufacturers and suppliers for some of our products, or sub-assemblies, components, and materials used
in our products, and if shipments from these manufacturers or suppliers are delayed or interrupted, or if the quality of the products,
components, or materials supplied do not meet our requirements, we may not be able to launch, manufacture, or ship our products in
a timely manner, or at all.
7) We depend on third-party manufacturers and suppliers for some of our products, or sub-assemblies, components, and materials used
in our products, and if shipments from these manufacturers or suppliers are delayed or interrupted, or if the quality of the products,
components, or materials supplied do not meet our requirements, we may not be able to launch, manufacture, or ship our products in
a timely manner, or at all.
8) If we are unable to increase our manufacturing or service capacity and develop and maintain operation of our manufacturing or
service capability, we may not be able to launch or support our products or services in a timely manner, or at all.
9) An interruption in our ability to manufacture our products or an inability to obtain key components or raw materials due to a
catastrophic disaster, infectious disease, or infrastructure failure could adversely affect our business.
10) We are unable to predict the extent to which public health crises, such as the COVID-19 pandemic, may adversely impact our business
operations and financial performance.
11) Any inability to effectively protect our proprietary technologies could harm our competitive position.
12)
Risks Related to Acquisitions, Including the Acquisition of GRAIL
Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of
acquisitions of businesses or technologies.
13)
Our acquisition of GRAIL remains subject to ongoing legal and regulatory proceedings in the United States and in the European
Union. On December 17, 2023, we announced that we will divest GRAIL. Adverse decisions by the EU and/or U.S. courts, the European
Commission, the FTC and/or other governmental or regulatory authorities, that have been issued in the past or may be issued in the
future, and/or other adverse consequences resulting from our decision to proceed with the completion of the acquisition, have
resulted in significant financial penalties, operational restrictions and increased costs, and could result in similar additional future
consequences or further result in loss of revenues, implicate our existing contractual arrangements or require us to divest all or a
portion of the assets or equity interests of GRAIL on terms that are materially worse than the terms on which we acquired GRAIL, any
or all of which, individually or in the aggregate, could have a material adverse effect on our business, financial condition and results
of operation.
14) We are subject to various uncertainties and restrictions while the Acquisition remains subject to ongoing regulatory and legal review
and proceedings related thereto, including the EC Divestment Decision, that could adversely affect our business, financial condition
and results of operations.
15)
The market price of our common stock may decline as a result of the Acquisition and the final outcomes of the regulatory and judicial
reviews thereof.
16) If we fail to maintain and successfully manage our strategic collaborations, our future results may be adversely impacted.
17) Litigation, other proceedings, or third-party claims of intellectual property infringement could require us to spend significant time and
money and could prevent us from selling our products or services.
18) If product or service liability lawsuits are successfully brought against us, we may face reduced demand for our products and incur
significant liabilities.
19) Our products, if used for the diagnosis of disease, could be subject to government regulation, and the regulatory approval and
maintenance process for such products may be expensive, time-consuming, and uncertain both in timing and in outcome.
20) If the FDA requires in the future that any of our LDT products be subject to regulatory clearance or approval, our business, financial
condition, or results of operations could be adversely affected.
21) Despite using commercially reasonable measures to secure our systems, networks, and products, security breaches, including with
respect to cybersecurity, and other disruptions could compromise our information, products, and services, disrupt our or our
customers’ operations, and expose us to liability, which could cause our business and reputation to suffer.
There are more but you get the idea. As usual, just because you make a declarative statement, it doesn't make it a fact. Some suggested reading:
https://d18rn0p25nwr6d.cloudfront.net/C ... b0894e.pdf
